Valuation: Alterity Therapeutics Limited

Market Cap 78.58M 67.34M 63M 57.59M 109M 7.52B 110M 745M 290M 3.78B 295M 289M 12.5B P/E 2026 *
-0.38x
P/E 2027 * -0.39x
Enterprise Value 33.32M 28.56M 26.72M 24.43M 46.09M 3.19B 46.58M 316M 123M 1.6B 125M 122M 5.3B EV / Sales 2026 *
12.1x
EV / Sales 2027 * 18x
Free-Float
92.1%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alterity Therapeutics Limited

1 day+3.06%
1 week-7.34%
Current month-7.34%
1 month-12.17%
3 months+1.00%
6 months+34.67%
Current year+26.25%
1 week 0.48
Extreme 0.475
0.54
1 month 0.48
Extreme 0.475
0.6
Current year 0.35
Extreme 0.35
0.78
1 year 0.35
Extreme 0.35
0.78
3 years 0.1
Extreme 0.1
0.95
5 years 0.1
Extreme 0.1
1.7
10 years 0.1
Extreme 0.1
20.5
Manager TitleAgeSince
Chief Executive Officer 65 06/01/2021
Director of Finance/CFO - 29/09/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 70 28/07/2005
Director/Board Member 47 07/08/2011
Director/Board Member 65 20/11/2025
Date Insider Type Main position Quantity % Market Cap.
15/06/26 Free

Director

1,000,000 0.0092%
07/01/26 Expiration

Chief Executive Officer

91,392,720 0.8404%
17/09/25 Expiration

Director

7,000,000 0.1052%
Change 5-day change 1-year change 3-year change Capi.($)
+3.06%-7.34%-15.83%+44.29% 76.4M
-0.74%+4.48%+3.74%+22.46% 51.61B
+1.01%+3.86%+471.68%+577.49% 44.89B
+0.16%+9.96%+36.14%+20.40% 42.77B
-0.66%+7.05%+18.59%+83.42% 42.58B
+0.88%-3.48%+17.20%+57.20% 31.82B
-0.12%+7.18%+33.73%+148.24% 17.33B
-0.53%+1.39% - - 16.63B
+0.58%+4.00%+7.17%+30.59% 14.76B
+1.15%+6.62%+84.49%+47.81% 14.09B
Average +0.43%+3.34%+72.99%+114.66% 27.66B
Weighted average by Cap. +0.01%+5.12%+100.54%+142.46%

Financials

2026 *2027 *
Net sales 2.74M 2.35M 2.2M 2.01M 3.8M 263M 3.84M 26.04M 10.13M 132M 10.31M 10.08M 437M 2.09M 1.79M 1.68M 1.53M 2.89M 200M 2.92M 19.83M 7.71M 101M 7.85M 7.68M 333M
Net income -14.76M -12.65M -11.84M -10.82M -20.42M -1.41B -20.64M -140M -54.46M -710M -55.43M -54.23M -2.35B -29.99M -25.7M -24.04M -21.98M -41.48M -2.87B -41.92M -285M -111M -1.44B -113M -110M -4.77B
Net Debt -45.25M -38.78M -36.28M -33.17M -62.59M -4.33B -63.26M -429M -167M -2.18B -170M -166M -7.2B -40.9M -35.05M -32.79M -29.98M -56.58M -3.92B -57.18M -388M -151M -1.97B -154M -150M -6.51B
Logo Alterity Therapeutics Limited
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.
Employees
9
Date Price Change Volume
24/08/26 A$0.5050 +3.06% 364,792
21/08/26 A$0.4900 -2.00% 767,057
20/08/26 A$0.5000 -0.99% 1,133,913
19/08/26 A$0.5050 +1.00% 334,345
18/08/26 A$0.5000 -5.66% 513,536
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.5050AUD
Average target price
3.275AUD
Spread / Average Target
+548.51%

Quarterly revenue - Rate of surprise